PL2613798T3 - Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów - Google Patents

Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów

Info

Publication number
PL2613798T3
PL2613798T3 PL11758644T PL11758644T PL2613798T3 PL 2613798 T3 PL2613798 T3 PL 2613798T3 PL 11758644 T PL11758644 T PL 11758644T PL 11758644 T PL11758644 T PL 11758644T PL 2613798 T3 PL2613798 T3 PL 2613798T3
Authority
PL
Poland
Prior art keywords
acid lipase
lysosomal acid
patients
treatment
lysosomal
Prior art date
Application number
PL11758644T
Other languages
English (en)
Other versions
PL2613798T5 (pl
Inventor
Anthony Quinn
Original Assignee
Synageva Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45806910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2613798(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2011/033699 external-priority patent/WO2011133960A2/en
Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp
Publication of PL2613798T3 publication Critical patent/PL2613798T3/pl
Publication of PL2613798T5 publication Critical patent/PL2613798T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01013—Sterol esterase (3.1.1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL11758644T 2010-09-09 2011-09-09 Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów PL2613798T5 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40301110P 2010-09-09 2010-09-09
US45601410P 2010-10-29 2010-10-29
US201161432372P 2011-01-13 2011-01-13
PCT/US2011/033699 WO2011133960A2 (en) 2010-04-23 2011-04-23 Lysosomal storage disease enzyme
EP11758644.6A EP2613798B2 (en) 2010-09-09 2011-09-09 Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
PCT/US2011/051096 WO2012050695A1 (en) 2010-09-09 2011-09-09 Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients

Publications (2)

Publication Number Publication Date
PL2613798T3 true PL2613798T3 (pl) 2015-07-31
PL2613798T5 PL2613798T5 (pl) 2018-06-29

Family

ID=45806910

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14200334T PL2977057T3 (pl) 2010-09-09 2011-09-09 Izolowana rekombinowana ludzka lizosomalna N-glikozylowana kwaśna lipaza
PL11758644T PL2613798T5 (pl) 2010-09-09 2011-09-09 Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14200334T PL2977057T3 (pl) 2010-09-09 2011-09-09 Izolowana rekombinowana ludzka lizosomalna N-glikozylowana kwaśna lipaza

Country Status (30)

Country Link
US (6) US8663631B2 (pl)
EP (3) EP2977057B1 (pl)
JP (3) JP5693728B2 (pl)
KR (1) KR20150038636A (pl)
CN (2) CN105457018A (pl)
AR (1) AR082953A1 (pl)
AU (1) AU2011314293B2 (pl)
BR (2) BR112013005673B1 (pl)
CA (2) CA3209456C (pl)
CL (1) CL2013000664A1 (pl)
CO (1) CO6710913A2 (pl)
CY (1) CY1116544T1 (pl)
DK (2) DK2613798T4 (pl)
ES (2) ES2535605T5 (pl)
HK (2) HK1220907A1 (pl)
HR (1) HRP20150438T1 (pl)
HU (1) HUE048688T2 (pl)
IL (2) IL225095A (pl)
ME (1) ME02062B (pl)
MX (2) MX2013002704A (pl)
NZ (3) NZ715014A (pl)
PL (2) PL2977057T3 (pl)
PT (2) PT2613798E (pl)
RS (1) RS53947B1 (pl)
RU (1) RU2550961C2 (pl)
SG (2) SG10201507199UA (pl)
SI (2) SI2977057T1 (pl)
SM (1) SMT201500108B (pl)
TW (1) TWI482625B (pl)
WO (1) WO2012050695A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398995C (en) * 2000-02-04 2014-09-23 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
EP2561069B1 (en) 2010-04-23 2017-03-08 Alexion Pharmaceuticals, Inc. Lysosomal storage disease enzyme
NZ715014A (en) * 2010-09-09 2018-10-26 Synageva Biopharma Corp Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
AU2012322811A1 (en) 2011-10-12 2014-05-01 Synageva Biopharma Corp. Recombinant human NaGlu protein and uses thereof
KR20140130443A (ko) * 2012-03-02 2014-11-10 시나게바 바이오파르마, 코포레이션 절두된 리소좀 산 리파제
CN106885910B (zh) * 2015-12-15 2018-12-21 上海吉涛生物科技有限公司 肿瘤易感微环境检测装置及试剂盒
WO2017218926A1 (en) 2016-06-17 2017-12-21 Alexion Pharmaceuticals, Inc. Lysosomal acid lipase deficiency compositions and methods
EP3504222A1 (en) 2016-08-23 2019-07-03 Alexion Pharmaceuticals, Inc. Method of purifying a heterologous protein from an egg white
US10633705B2 (en) 2016-10-14 2020-04-28 Alexion Pharmaceuticals, Inc. N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11396499B2 (en) 2018-12-12 2022-07-26 University Of Washington Lysosomal acid lipase assay
WO2021117122A1 (ja) * 2019-12-10 2021-06-17 株式会社リボルナバイオサイエンス ライソゾーム酸性リパーゼ欠損症の予防または治療剤

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001985D0 (sv) 1990-06-01 1990-06-01 Astra Ab New chemical products
WO1992016212A1 (en) 1991-03-13 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996004001A1 (en) 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
ES2326705T3 (es) 1995-09-14 2009-10-16 Virginia Tech Intellectual Properties, Inc. Produccion de enzimas lisosomicas en sistemas de expresion basados en plantas.
HU227189B1 (en) 1996-09-13 2010-10-28 Transkaryotic Therapies Therapy for alpha-galactosidase a deficiency
WO2000009153A1 (en) 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US7339033B2 (en) 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
KR20010101131A (ko) 1998-12-07 2001-11-14 추후기재 폼페병의 치료 방법
US7033780B1 (en) 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
CA2398995C (en) 2000-02-04 2014-09-23 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
WO2001097829A2 (en) 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040038365A1 (en) 2000-10-31 2004-02-26 Yonghong Xiao Regulation of human lysosomal acid lipase
US20030064437A1 (en) 2000-11-15 2003-04-03 Nick Wan Expression system for recombinant proteins
US20020193303A1 (en) 2001-01-25 2002-12-19 Millennium Pharmaceuticals, Inc. 58860, a human cholesteryl ester hydrolase and uses therefor
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
WO2003064614A2 (en) 2002-01-30 2003-08-07 Yale University Transport peptides and uses therefor
AU2003222825A1 (en) 2002-04-16 2003-10-27 Universiteit Gent A marker for measuring liver cirrhosis
CA2499188A1 (en) 2002-09-27 2004-04-08 Cold Spring Harbor Laboratory Cell-based rna interference and related methods and compositions
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2006002053A2 (en) 2004-06-15 2006-01-05 Mayo Foundation For Medical Education And Research Helicases
ATE472333T1 (de) 2004-08-19 2010-07-15 Biogen Idec Inc Rückfaltung von proteinen der transforming-growth-factor-beta-familie
US20070270367A1 (en) 2005-05-18 2007-11-22 University Of Kentucky Research Foundation Rybozyme-catalyzed insertion of targeted sequences into RNA
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
PL377180A1 (pl) 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
ES2744125T3 (es) 2005-10-05 2020-02-21 Alexion Pharma Inc Producción rápida de virus de título elevado
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US20070267249A1 (en) 2006-05-18 2007-11-22 Cullen David P Roof safety system
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
WO2007137303A2 (en) 2006-05-24 2007-11-29 Myelin Repair Foundation, Inc. Permeability of blood-brain barrier
US8143265B2 (en) 2007-04-16 2012-03-27 Meharry Medical College Method of treating atherosclerosis
WO2008131431A2 (en) 2007-04-23 2008-10-30 St. Louis University Modulation of blood brain barrier protein expression
CA2688240A1 (en) 2007-05-24 2008-12-04 The United States Government As Represented By The Department Of Veterans Affairs Intranuclear protein transduction through a nucleoside salvage pathway
PT2164501E (pt) 2007-05-31 2016-06-02 Paradigm Biopharmaceuticals Ltd Xilanos sulfatados para tratamento ou profilaxia de doenças respiratórias
WO2009008725A2 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
US20100291060A1 (en) 2007-08-29 2010-11-18 Shire Human Genetic Therapies, Inc Subcutaneous administration of alpha-galactosidase a
US8431770B2 (en) 2008-01-07 2013-04-30 Synageva Biopharma Corp. Method of producing sialytransferase-modified proteins
WO2010033854A2 (en) 2008-09-19 2010-03-25 Synageva Biopharma Corp. Avian derived fusion proteins
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
WO2010078515A2 (en) 2009-01-02 2010-07-08 Zacharon Pharmaceuticals, Inc. Polymer end group detection
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
ES2576853T3 (es) 2009-07-03 2016-07-11 Inserm - Institut National De La Santé Et De La Recherche Médicale Compuestos dirigidos al receptor del manosa 6-fosfato independiente de cationes
US20110033699A1 (en) 2009-07-23 2011-02-10 Nitto Denko Corporation Pressure-sensitive adhesive tape
RU2608520C2 (ru) 2009-10-19 2017-01-19 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
KR101077618B1 (ko) 2009-11-13 2011-10-27 경북대학교 산학협력단 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
US20150030582A1 (en) 2010-04-23 2015-01-29 Synageva Biopharma Corp. Lysosomal Storage Disease Enzyme
EP2561069B1 (en) 2010-04-23 2017-03-08 Alexion Pharmaceuticals, Inc. Lysosomal storage disease enzyme
NZ715014A (en) 2010-09-09 2018-10-26 Synageva Biopharma Corp Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2012112677A2 (en) 2011-02-15 2012-08-23 Children's Hospital Medical Center Methods for treating lysosomal acid lipase deficiency
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
WO2012159052A2 (en) 2011-05-18 2012-11-22 Children's Hospital Medical Center Targeted delivery of proteins across the blood brain barrier
CN103764824B (zh) 2011-06-20 2018-04-24 西奈山医学院 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法
WO2012177639A2 (en) 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
US20130027021A1 (en) 2011-07-28 2013-01-31 Abb Inc. Current sensor
CN108165593A (zh) 2011-08-03 2018-06-15 凤凰组织修复公司 胶原蛋白7及相关方法
AU2012322811A1 (en) 2011-10-12 2014-05-01 Synageva Biopharma Corp. Recombinant human NaGlu protein and uses thereof

Also Published As

Publication number Publication date
EP2613798A1 (en) 2013-07-17
HUE048688T2 (hu) 2020-08-28
NZ608292A (en) 2014-10-31
BR122019021757B1 (pt) 2020-12-08
CN103200958A (zh) 2013-07-10
CA2810999C (en) 2023-10-03
IL225095A (en) 2016-05-31
WO2012050695A1 (en) 2012-04-19
ES2769836T3 (es) 2020-06-29
US20190282671A1 (en) 2019-09-19
NZ700824A (en) 2016-03-31
US20120064055A1 (en) 2012-03-15
EP2977057A1 (en) 2016-01-27
BR112013005673A2 (pt) 2017-09-19
JP2015052014A (ja) 2015-03-19
ES2535605T3 (es) 2015-05-13
US20160051638A1 (en) 2016-02-25
NZ715014A (en) 2018-10-26
EP2613798B1 (en) 2015-02-11
CO6710913A2 (es) 2013-07-15
HRP20150438T1 (hr) 2015-05-22
RU2013110491A (ru) 2014-11-10
AR082953A1 (es) 2013-01-23
CA3209456C (en) 2025-05-06
BR112013005673B1 (pt) 2020-12-15
IL245283B (en) 2019-02-28
DK2613798T3 (en) 2015-04-20
US10166274B2 (en) 2019-01-01
PT2977057T (pt) 2020-02-18
EP2613798B2 (en) 2018-01-24
JP2013540733A (ja) 2013-11-07
JP6156882B2 (ja) 2017-07-05
MX2013002704A (es) 2013-09-13
ME02062B (me) 2015-05-20
DK2977057T3 (da) 2020-02-10
ES2535605T5 (es) 2018-04-30
CN105457018A (zh) 2016-04-06
RS53947B1 (sr) 2015-08-31
CA3209456A1 (en) 2012-04-19
IL245283A0 (en) 2016-06-30
US20220362350A1 (en) 2022-11-17
TWI482625B (zh) 2015-05-01
US20250025538A1 (en) 2025-01-23
SI2977057T1 (sl) 2020-03-31
US8663631B2 (en) 2014-03-04
EP3650039A1 (en) 2020-05-13
JP2016145257A (ja) 2016-08-12
US12076376B2 (en) 2024-09-03
CA2810999A1 (en) 2012-04-19
DK2613798T4 (en) 2018-04-16
MX365007B (es) 2019-05-20
EP2977057B1 (en) 2019-11-06
RU2550961C2 (ru) 2015-05-20
CL2013000664A1 (es) 2013-10-04
TW201225971A (en) 2012-07-01
US20140348752A1 (en) 2014-11-27
JP5693728B2 (ja) 2015-04-01
SG188456A1 (en) 2013-04-30
AU2011314293A1 (en) 2013-04-04
SI2613798T1 (sl) 2015-05-29
PL2613798T5 (pl) 2018-06-29
KR20150038636A (ko) 2015-04-08
PL2977057T3 (pl) 2020-06-01
PT2613798E (pt) 2015-06-02
HK1220907A1 (zh) 2017-05-19
SMT201500108B (it) 2015-07-09
SI2613798T2 (en) 2018-05-31
AU2011314293B2 (en) 2015-06-04
HK1215532A1 (en) 2016-09-02
US11400141B2 (en) 2022-08-02
SG10201507199UA (en) 2015-10-29
CY1116544T1 (el) 2018-03-07

Similar Documents

Publication Publication Date Title
PL2613798T5 (pl) Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów
CY2021031I2 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
LT2596786T (lt) Eikozapentaeno rūgšties etilo esterio naudojimas hipertriglicidemijai gydyti
HRP20181378T1 (hr) Postupci liječenja pedijatrijskih pacijenata deksmedetomidinom
IL218324B (en) Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
BR112013013684A2 (pt) tratamento das condiçóes mediadas por jak-2
JP2013512229A5 (ja) 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｐｐ−ｉｖ阻害薬による治療
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
DK3162386T3 (da) Implanterbare medicinske indretninger
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
ZA201301601B (en) Treatment of diseases
HRP20180780T1 (hr) Liječenje gihta i hiperurikemije
IL215467A (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
PL2627345T3 (pl) Preparaty do leczenia chorób górnych dróg oddechowych
IL232384A (en) Use of lupanate compounds or lupanic acid for the preparation of anti-gout drugs
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
HRP20190169T1 (hr) Postupci liječenja povećanja tjelesne težine inducirane antipsihoticima
PL2632475T3 (pl) Kompozycje do leczenia wrzodów peryferyjnych o zróżnicowanym pochodzeniu
FI20096402A0 (fi) Veriryhmästatuksen käyttö II
HRP20181979T1 (hr) Medicinsko ljepilo i postupak njegove proizvodnje
PL3363439T3 (pl) Kompozycje terapeutyczne do leczenia cukrzycowej polineuropatii symetrycznej
FR2964854B1 (fr) Gouttieres dentaires universelles
LT2531124T (lt) Prietaisai odos pažeidimams gydyti
HRP20151393T8 (hr) UPORABA BENZIDAMINA U LIJEČENJU BOLESTI KOJE SU p40-OVISNE